Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its strategy to expand beyond oncology and secure a new growth engine with Verona's newly approved COPD treatment, Ohtuvayre.

The transaction, one of the largest in Merck’s storied history, was unveiled Wednesday, and positions the company to dominate a long-underserved corner of respiratory care, just as its multibillion-dollar cancer drug Keytruda approaches patent expiration in 2028.

A Pulmonary Power Play

Ohtuvayre — Verona’s crown jewel — is a first-in-class inhaled therapy for chronic obstructive pulmonary disease (COPD) and the first novel mechanism for the condition in over two decades. Approved by the FDA in June 2024, the drug combines bronchodilation with anti-inflammatory effects, targeting persistently symptomatic patients where existing treatments have failed.

Merck is wagering that Ohtuvayre could anchor its respiratory portfolio for the next generation, and signals its most aggressive bet yet on therapeutic diversification.

“This novel treatment addresses a critical unmet need in COPD,” Merck CEO Robert Davis said in a statement. “It’s a strategic fit for our pipeline and future growth.”

The therapy is also in trials for bronchiectasis, a separate but related lung condition — a potential avenue for market expansion.

Diversifying Beyond Oncology

The Verona acquisition is the latest in a spree of high-stakes deals aimed at future-proofing Merck’s pipeline:

• Prometheus Biosciences for $10.8B, adding an autoimmune drug candidate (2023)

• Acceleron Pharma for $11.5B, bringing a rare disease and anemia treatment (2021)

• A $22B collaboration with Daiichi Sankyo to co-develop cancer ADCs (2023)

• A $2B investment in a Chinese cardiovascular therapy (recent)

Each of these bets is part of a calculated chess game to soften the financial blow of Keytruda’s eventual loss of exclusivity, which has been Merck’s single largest revenue stream.

The Deal Mechanics and Legal Backing

The $10B Verona transaction, expected to close by year-end, is contingent on both regulatory approval and shareholder sign-off.

• Merck is advised by Freshfields LLP, with Gibson Dunn handling antitrust matters

• Verona Pharma is represented by Latham & Watkins LLP

Looking Back: Merck’s Mega-Deals in Perspective

Merck’s biggest deal remains the $41.1B reverse merger with Schering-Plough in 2009 — a deal that rewrote pharma M&A playbooks. Since then, its top five deals have included Prometheus, Acceleron, and now Verona, reflecting a shift toward precision medicine and innovative biotech.

Each deal, including Verona, has been more than a numbers game. They represent strategic repositioning in areas of unmet clinical need, from cancer to cardiovascular to now chronic respiratory illness.

“We are building an innovation engine that is sustainable, diversified, and science-driven,” Davis added.